CRNX - Company ID 0001658247
The table below shows Crinetics Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$124.70M | -$88.45M | -$52.86M | -$40.72M | -$13.54M | -$20.07M |
| Capital expenditure | $820.00K | $1.24M | $1.33M | $16.00K | $87.00K | $116.00K |
| Investing cash flow | -$252.36M | -$85.96M | $309.00K | $48.76M | -$43.38M | $32.50M |
| Dividends paid | - | - | - |
Crinetics Pharmaceuticals, Inc. reported operating cash flow of -$377.92M for fiscal year 2025. That is down 64.2% from -$230.19M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.47M (FY 2016) to -$377.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $389.88M | $4.44M | $393.57M | $484.00K | $1.78M | $57.00K |